Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations
Open Access
- 27 August 2009
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 17 (1), 117-131
- https://doi.org/10.1038/gt.2009.104
Abstract
Aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) is required for the biosynthesis of photoreceptor phosphodiesterase (PDE). Gene defects in AIPL1 cause a heterogeneous set of conditions ranging from Leber's congenital amaurosis (LCA), the severest form of early-onset retinal degeneration, to milder forms such as retinitis pigmentosa (RP) and cone-rod dystrophy. In mice, null and hypomorphic alleles cause retinal degeneration similar to human LCA and RP, respectively. Thus these mouse models represent two ends of the disease spectrum associated with AIPL1 gene defects in humans. We evaluated whether adeno-associated virus (AAV)-mediated gene replacement therapy in these models could restore PDE biosynthesis in rods and cones and thereby improve photoreceptor survival. We validated the efficacy of human AIPL1 (isoform 1) replacement gene controlled by a promoter derived from the human rhodopsin kinase (RK) gene, which is active in both rods and cones. We found substantial and long-term rescue of the disease phenotype as a result of transgene expression. This is the first gene therapy study in which both rods and cones were targeted successfully with a single photoreceptor-specific promoter. We propose that the vector and construct design used in this study could serve as a prototype for a human clinical trial.Keywords
This publication has 49 references indexed in Scilit:
- Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectorsHuman Molecular Genetics, 2009
- AAV-Mediated Gene Therapy for Retinal Degeneration in therd10Mouse Containing a Recessive PDEβ MutationInvestigative Opthalmology & Visual Science, 2008
- Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kineticsProceedings of the National Academy of Sciences, 2008
- Leber congenital amaurosis: Genes, proteins and disease mechanismsProgress in Retinal and Eye Research, 2008
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Novel Adeno-Associated Virus Serotypes Efficiently Transduce Murine PhotoreceptorsJournal of Virology, 2007
- Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectivesGene Therapy, 2004
- Prospects for Gene TherapyPublished by Wiley ,2003
- Complete exon-intron structure of the RPGR-interacting protein (RPGRIP1) gene allows the identification of mutations underlying Leber congenital amaurosisEuropean Journal of Human Genetics, 2001